Cryosite is an Australian public listed company, established in 2000 with the specific objective of providing specialised services to a wide range of clients including the research, medical, pharmaceutical and biotechnology industries.

In 2001, Cryosite launched Australia’s first private cord blood service. Cryosite’s laboratories and cryogenic storage facilities are fully licenced by the Therapeutic Goods Administration (TGA) for the collection, processing, storage and release of autologous cord blood. To date, more than 600 obstetricians have participated in collecting cord blood for our clients at more than 250 hospitals and birthing centers throughout Australia, New Zealand, Hong Kong, Singapore, Noumea, and Japan. We routinely collect cord blood from every state in Australia.

In 2002 Cryosite expanded its range of services to include the provision of clinical trial logistics services to pharmaceutical companies and clinical research organisations. Outsourcing the management of clinical trial supplies and samples plays a particularly effective role in clinical development and allows clinical research organisations, doctors and researchers to focus their resources on other key aspects of trial management and development. This is particularly beneficial as clinical trials become more complex and costly. Our blue chip client profile recognise the benefits of working with a customer orientated company and some of our clients include Pfizer (Australia) Pty, Bristol-Myers Squibb Pty Ltd, Schering-Plough, Johnson & Johnson Research Pty Ltd and St Vincent’s Hospital (Sydney).

In 2004 Cryosite entered a collaboration with the Centre for Blood Therapies at the Peter MacCallum Cancer Institute (Peter Mac) in Melbourne, Vic. The Peter Mac is one of the world’s largest groups dedicated to cancer treatment and research and their range of services includes the collection, processing and cryopreservation of adult blood stem cells which are then stored until they are required for infusion.

This collaboration with Cryosite is part of an innovative approach taken by the Peter Mac to provide patients who are about to undergo high dose chemotherapy for the treatment of cancer, to have their blood stem cells collected and stored for potential therapeutic use in the future. As chemotherapy inhibits the ability of the bone marrow to make new blood cells, stem cells which have been stored prior to treatment can be used to restore normal bone marrow function. Cryosite provides the specialist cryogenic shipping and storage services that are required for the long-term storage of the blood stem cells.

Operations are carried out in a new state-of-the-art purpose built 2000m2 NATA accredited (ISO/IEC 17025) facility, that operates to World’s Best Practice and all applicable GMP and GCP standards. The facility is AQIS approved under section 46a of the Quarantine Act for the quarantine of class 5.1 goods. The facility is secured and monitored 24 hours a day and provides clients with a range of storage conditions and options including ambient (18-25°C), refrigerator (2-8°C), frozen (-20 to -80°C) and cryogenic (liquid nitrogen). Our Quality standards ensure compliance with all necessary regulatory requirements.

The leading provider of specialist ambient, cold-room, ultra-low temperature and cryogenic storage, all Cryosite staff have formal scientific qualifications and understand the high level of importance that needs to be associated with your samples. Client satisfaction is critical to our success, and is part of our ongoing quality assessment. Our strong customer focus allows us to respond quickly and efficiently to emerging requirements and meet the growing needs of the marketplace.